Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (9)
Type
(
2 selected
)
Type
Guidance (370)
NICE advice (1)
Quality standard (12)
Guidance programme
Guidance programme
Clinical guidelines (32)
Diagnostics guidance (6)
Diagnostics guidanceDiagnostics guidance (6)
Health technology evaluations (10)
Highly specialised technologies guidance (10)
Interventional procedures guidance (6)
Interventional procedures guidanceInterventional procedures guidance (23)
Medical technologies guidance (4)
Medical technologies guidanceMedical technologies guidance (9)
NICE guidelines (36)
Public health guidelines (1)
Technology appraisal guidance (265)
Apply filters
Showing 1 to 50 of 382
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Type: Quality standard
Remove Type: Quality standard filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
Technology appraisal guidance
TBC
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]
Technology appraisal guidance
TBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]
Technology appraisal guidance
TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533
Technology appraisal guidance
TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Technology appraisal guidance
TBC
Acute Respiratory Infection in over 16s: Initial assessment and management
NICE guideline
30 October 2023
Acute respiratory infection in over 16s: initial assessment and management, including using virtual wards
Quality standard
31 October 2023
Adrenal insufficiency: acute and long-term management
NICE guideline
14 August 2024
Alcohol-mediated perivascular renal denervation for resistant hypertension
Interventional procedures guidance
9 December 2024
Algorithm-based remote monitoring of heart failure risk data in people with cardiac implantable electronic devices
Diagnostics guidance
10 July 2024
Alzheimer's disease (early) - gantenerumab [ID6142]
Technology appraisal guidance
TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
Highly specialised technology
TBC
Artificial intelligence (AI) software to help clinical decision making in stroke
Diagnostics guidance
15 November 2023
Artificial Intelligence for dermatology - skin cancer: reduce referrals by early detection of benign skin lesions (provisional title)
Diagnostics guidance
TBC
Artificial intelligence technologies to aid contouring for radiotherapy treatment planning: early value assessment
Health technology evaluation
27 September 2023
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment
Health technology evaluation
TBC
Asthma: diagnosis, monitoring and chronic asthma management
NICE guideline
31 July 2024
Asunercept for treating glioblastoma [1301]
Technology appraisal guidance
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Technology appraisal guidance
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]
Technology appraisal guidance
TBC
ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]
Technology appraisal guidance
TBC
Atogepant for preventing migraine [ID5090]
Technology appraisal guidance
TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Technology appraisal guidance
TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Technology appraisal guidance
TBC
Avapritinib for treating advanced systemic mastocytosis ID3770
Technology appraisal guidance
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Technology appraisal guidance
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Technology appraisal guidance
TBC
AZD 3152 for preventing COVID-19 [ID6282]
Technology appraisal guidance
TBC
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]
Technology appraisal guidance
TBC
Baricitinib for treating severe alopecia areata [ID3979]
Technology appraisal guidance
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Technology appraisal guidance
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Technology appraisal guidance
23 August 2023
Belumosudil for treating chronic graft versus host disease after 2 or more lines of systemic therapy [ID4021]
Technology appraisal guidance
22 November 2023
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Technology appraisal guidance
TBC
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]
Technology appraisal guidance
31 January 2024
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Technology appraisal guidance
TBC
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal guidance
20 February 2019
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]
Technology appraisal guidance
TBC
Bimekizumab for treating active psoriatic arthritis [ID4009]
Technology appraisal guidance
4 October 2023
Bimekizumab for treating axial spondyloarthritis [ID6245]
Technology appraisal guidance
11 October 2023
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]
Technology appraisal guidance
TBC
Biodegradable subacromial spacer insertion for rotator cuff tears
Interventional procedures guidance
15 November 2023
Bipolar disorder: assessment and management (extraordinary review)
NICE guideline
TBC
Birch bark extract for treating skin wounds associated with dystrophic and junctional epidermolysis bullosa [ID1505]
Technology appraisal guidance
20 September 2023
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]
Technology appraisal guidance
TBC
Breast cancer guidelines
NICE guideline
TBC
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Technology appraisal guidance
TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Technology appraisal guidance
TBC
Current page
1
2
3
…
8
Page
1
of
8
Next page
Results per page
10
25
50
All
Back to top